|
The study, from the brain-tumor research lab of Dr. John Kuo,assistant professor of neurological surgery and human oncology atUW School of Medicine and Public Health, also reports success for acombination therapy that knocks out signaling of multiple membersof the epidermal growth factor receptor (EGFR) family inbrain-cancer cells. The late U.S. Sen. Edward M. Kennedy died of GBM in 2009. Peoplediagnosed with GBM live on average for only 15 months afterdiagnosis, even after undergoing aggressive surgery, radiation andchemotherapy. Earlier research from Dr. Kuo and other scientistsshowed that GBM cancer stem cells escape current treatments andproliferate rapidly to cause tumor recurrence. Several years ago, research suggested that a drug engineered totarget EGFR signaling might work against GBM because many braincancers carried EGFR mutations. Excessive and abnormal EGFRsignaling spurs the growth of cancer cells. Although cetuximab, amonoclonal-antibody drug, was successful in clinical trials forpatients with lung, colorectal, and head and neck cancers, itfailed against GBM. Research by Dr. Paul Clark, a scientist in Kuo's lab and thestudy's lead author, shows why. When cetuximab treatment switchesoff EGFR activity and should inhibit cancer-cell growth, cancerstem cells compensate by turning on two other EGFR family receptors(ERBB2 and ERBB3) and continue to grow. One of these receptors,ERBB2, is implicated in certain types of chemotherapy-resistantbreast cancer. Fortunately, another novel drug already approved bythe FDA, lapatinib, inhibits ERBB2 activity and signaling bymultiple EGFR members. This study shows that cancer stem-cell growth was markedlyinhibited by lapatinib treatment, which results in combinedknockout of multiple EGFR family members. "This is good news, because these drugs target an importantmechanism for the (GBM) cancer cells to grow so quickly and evadecurrent therapies, and these molecularly targeted drugs are alsowell-tolerated by patients and have minimal side effects," Dr.Clark said. The paper was published in the most recent issue of Neoplasia , an international journal for oncology research. Kuo, director of the Comprehensive Brain Tumor Program at UW Healthand chair of the Carbone Cancer Center brain tumor group, said thatresults of several brain cancer clinical trials with these noveldrugs and other new strategies are pending or underway. The e-commerce company in China offers quality products such as Chemical Mixing Machine Manufacturer , Precision Grinding Machine, and more. For more , please visit Air Stream Dryer today!
Related Articles -
Chemical Mixing Machine Manufacturer, Precision Grinding Machine,
|
